CO2022000186A2 - Nuevos compuestos heterocíclicos - Google Patents
Nuevos compuestos heterocíclicosInfo
- Publication number
- CO2022000186A2 CO2022000186A2 CONC2022/0000186A CO2022000186A CO2022000186A2 CO 2022000186 A2 CO2022000186 A2 CO 2022000186A2 CO 2022000186 A CO2022000186 A CO 2022000186A CO 2022000186 A2 CO2022000186 A2 CO 2022000186A2
- Authority
- CO
- Colombia
- Prior art keywords
- heterocyclic compounds
- compounds
- new heterocyclic
- new
- processes
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención proporciona nuevos compuestos heterocíclicos que tienen la fórmula general (I) en donde R1, R2, X e Y son como se definen en la presente, composiciones que incluyen los compuestos, procesos para fabricar los compuestos y métodos para usar los compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19185088 | 2019-07-09 | ||
| PCT/EP2020/069074 WO2021005034A1 (en) | 2019-07-09 | 2020-07-07 | New heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022000186A2 true CO2022000186A2 (es) | 2022-01-17 |
Family
ID=67220669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0000186A CO2022000186A2 (es) | 2019-07-09 | 2022-01-13 | Nuevos compuestos heterocíclicos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220242876A1 (es) |
| EP (1) | EP3997096B1 (es) |
| JP (1) | JP7649283B2 (es) |
| KR (1) | KR20220034104A (es) |
| CN (1) | CN114096545A (es) |
| AR (1) | AR119376A1 (es) |
| AU (1) | AU2020311584A1 (es) |
| BR (1) | BR112021026899A2 (es) |
| CA (1) | CA3145338A1 (es) |
| CL (1) | CL2022000019A1 (es) |
| CO (1) | CO2022000186A2 (es) |
| CR (1) | CR20220004A (es) |
| IL (1) | IL288987A (es) |
| MX (1) | MX2022000243A (es) |
| PE (1) | PE20220515A1 (es) |
| PH (1) | PH12021553249A1 (es) |
| TW (1) | TW202116781A (es) |
| WO (1) | WO2021005034A1 (es) |
| ZA (1) | ZA202110352B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| EP4474017A3 (en) | 2018-08-13 | 2025-02-26 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| WO2021048242A1 (en) | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| CA3190277A1 (en) | 2020-09-03 | 2022-03-10 | Joerg Benz | Heterocyclic compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2844310A1 (en) * | 2011-08-19 | 2013-02-28 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2014099633A2 (en) * | 2012-12-19 | 2014-06-26 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US10323038B2 (en) * | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2018134698A1 (en) * | 2017-01-23 | 2018-07-26 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
| JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| PE20200664A1 (es) * | 2017-08-29 | 2020-06-11 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso |
| EP3737680A1 (en) * | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| CA3143280A1 (en) * | 2019-07-03 | 2021-01-07 | F. Hoffmann-La Roche Ag | Heterocyclic monoacylglycerol lipase (magl) inhibitors |
-
2020
- 2020-07-07 WO PCT/EP2020/069074 patent/WO2021005034A1/en not_active Ceased
- 2020-07-07 AU AU2020311584A patent/AU2020311584A1/en not_active Abandoned
- 2020-07-07 MX MX2022000243A patent/MX2022000243A/es unknown
- 2020-07-07 KR KR1020227000611A patent/KR20220034104A/ko not_active Ceased
- 2020-07-07 PE PE2021002265A patent/PE20220515A1/es unknown
- 2020-07-07 CA CA3145338A patent/CA3145338A1/en active Pending
- 2020-07-07 JP JP2022500908A patent/JP7649283B2/ja active Active
- 2020-07-07 CR CR20220004A patent/CR20220004A/es unknown
- 2020-07-07 CN CN202080050165.3A patent/CN114096545A/zh active Pending
- 2020-07-07 PH PH1/2021/553249A patent/PH12021553249A1/en unknown
- 2020-07-07 BR BR112021026899A patent/BR112021026899A2/pt not_active Application Discontinuation
- 2020-07-07 EP EP20740259.5A patent/EP3997096B1/en active Active
- 2020-07-08 TW TW109123050A patent/TW202116781A/zh unknown
- 2020-07-08 AR ARP200101928A patent/AR119376A1/es not_active Application Discontinuation
-
2021
- 2021-12-13 ZA ZA2021/10352A patent/ZA202110352B/en unknown
- 2021-12-14 IL IL288987A patent/IL288987A/en unknown
-
2022
- 2022-01-04 CL CL2022000019A patent/CL2022000019A1/es unknown
- 2022-01-06 US US17/569,749 patent/US20220242876A1/en active Pending
- 2022-01-13 CO CONC2022/0000186A patent/CO2022000186A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114096545A (zh) | 2022-02-25 |
| WO2021005034A1 (en) | 2021-01-14 |
| EP3997096C0 (en) | 2024-08-28 |
| US20220242876A1 (en) | 2022-08-04 |
| AU2020311584A1 (en) | 2022-01-20 |
| EP3997096B1 (en) | 2024-08-28 |
| BR112021026899A2 (pt) | 2022-05-10 |
| CA3145338A1 (en) | 2021-01-14 |
| PH12021553249A1 (en) | 2023-02-27 |
| TW202116781A (zh) | 2021-05-01 |
| EP3997096A1 (en) | 2022-05-18 |
| AR119376A1 (es) | 2021-12-15 |
| ZA202110352B (en) | 2022-08-31 |
| MX2022000243A (es) | 2022-02-03 |
| CL2022000019A1 (es) | 2022-10-21 |
| CR20220004A (es) | 2022-01-31 |
| IL288987A (en) | 2022-02-01 |
| PE20220515A1 (es) | 2022-04-07 |
| JP7649283B2 (ja) | 2025-03-19 |
| JP2022539604A (ja) | 2022-09-12 |
| KR20220034104A (ko) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021007056A2 (es) | Nuevos compuestos heterocíclicos | |
| CO2023014721A2 (es) | Compuestos heterocíclicos | |
| CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
| CO2021002382A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
| CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
| CL2021000361A1 (es) | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa | |
| CL2023000594A1 (es) | Compuestos heterocíclicos | |
| CO2022000186A2 (es) | Nuevos compuestos heterocíclicos | |
| CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
| UY37487A (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| MX2018000511A (es) | Derivados de fenoximetilo. | |
| CO2022002336A2 (es) | Compuestos heterocíclicos | |
| CO2022002000A2 (es) | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) | |
| CR20140079A (es) | Aminoquinazolinas como inhibidores de quinasa | |
| CO2017008600A2 (es) | Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos | |
| CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos | |
| CR20220091A (es) | Compuestos de 4,4a, 5,7,8,8a-hexapirido [4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
| MX2019013979A (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| BR112013028368A2 (pt) | novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona | |
| UY38749A (es) | Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas | |
| UY38943A (es) | Nuevas heteroaril piperidiniletanonas sustituidas de 6 miembros | |
| CL2020003214A1 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 | |
| CO2021002415A2 (es) | Derivados de heteroarilo bicíclicos | |
| UY38940A (es) | Nuevas piridiniloxi piperidiniletanonas sustituidas | |
| CO2025001103A2 (es) | Derivados de tetrahidrotiazepina bicíclicos |